Shanghai Allist Pharmaceuticals Co., Ltd.

SHSE:688578 Stock Report

Market Cap: CN¥27.5b

Shanghai Allist Pharmaceuticals Past Earnings Performance

Past criteria checks 6/6

Shanghai Allist Pharmaceuticals has been growing earnings at an average annual rate of 84.5%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 67% per year. Shanghai Allist Pharmaceuticals's return on equity is 26.7%, and it has net margins of 40.5%.

Key information

84.5%

Earnings growth rate

85.1%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate67.0%
Return on equity26.7%
Net Margin40.5%
Next Earnings Update24 Apr 2025

Recent past performance updates

Recent updates

Shanghai Allist Pharmaceuticals Co., Ltd.'s (SHSE:688578) Intrinsic Value Is Potentially 86% Above Its Share Price

Dec 15
Shanghai Allist Pharmaceuticals Co., Ltd.'s (SHSE:688578) Intrinsic Value Is Potentially 86% Above Its Share Price

Shanghai Allist Pharmaceuticals Co., Ltd.'s (SHSE:688578) Shares Bounce 43% But Its Business Still Trails The Market

Oct 08
Shanghai Allist Pharmaceuticals Co., Ltd.'s (SHSE:688578) Shares Bounce 43% But Its Business Still Trails The Market

Does Shanghai Allist Pharmaceuticals (SHSE:688578) Deserve A Spot On Your Watchlist?

Sep 23
Does Shanghai Allist Pharmaceuticals (SHSE:688578) Deserve A Spot On Your Watchlist?

Shanghai Allist Pharmaceuticals Co., Ltd. (SHSE:688578) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected

Apr 30
Shanghai Allist Pharmaceuticals Co., Ltd. (SHSE:688578) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected

Should You Be Adding Shanghai Allist Pharmaceuticals (SHSE:688578) To Your Watchlist Today?

Apr 01
Should You Be Adding Shanghai Allist Pharmaceuticals (SHSE:688578) To Your Watchlist Today?

Optimistic Investors Push Shanghai Allist Pharmaceuticals Co., Ltd. (SHSE:688578) Shares Up 26% But Growth Is Lacking

Mar 04
Optimistic Investors Push Shanghai Allist Pharmaceuticals Co., Ltd. (SHSE:688578) Shares Up 26% But Growth Is Lacking

Revenue & Expenses Breakdown

How Shanghai Allist Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SHSE:688578 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 243,2041,2971,419297
30 Jun 242,8461,0921,317301
31 Mar 242,4859151,215282
31 Dec 232,0186441,051281
30 Sep 231,621487882230
30 Jun 231,239312736188
31 Mar 23956188613190
31 Dec 22791131524176
30 Sep 22560-63489175
30 Jun 22709123432197
31 Mar 2260440399213
31 Dec 2153018367201
30 Sep 2148829327202
30 Jun 21122-255278174
31 Mar 2137-289233160
31 Dec 201-311185175
30 Sep 201-354199186
31 Mar 201-299250212
31 Dec 191-398235160
31 Dec 185-972291
31 Dec 178-392036

Quality Earnings: 688578 has high quality earnings.

Growing Profit Margin: 688578's current net profit margins (40.5%) are higher than last year (30%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 688578 has become profitable over the past 5 years, growing earnings by 84.5% per year.

Accelerating Growth: 688578's earnings growth over the past year (166.3%) exceeds its 5-year average (84.5% per year).

Earnings vs Industry: 688578 earnings growth over the past year (166.3%) exceeded the Pharmaceuticals industry -2.5%.

Return on Equity

High ROE: 688578's Return on Equity (26.7%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 18:34
End of Day Share Price 2024/12/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shanghai Allist Pharmaceuticals Co., Ltd. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Feifei XuChina Merchants Securities Co. Ltd.
Zhu ChenCitic Securities Co., Ltd.
Tan Huan GanCitic Securities Co., Ltd.